Back to Journals » Biologics: Targets and Therapy
Biologics: Targets and Therapy
- View all (605)
- Volume 20, 2026 (18)
- Volume 19, 2025 (56)
- Volume 18, 2024 (35)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Journal Articles:
- 605 records -
Vunakizumab for IL-17A–Mediated Diseases: A Review in Psoriasis and Spondyloarthritis
Yan H, Chen Y, Song Y, Yan M, Yan K
Biologics: Targets and Therapy 2026, 20:500475
Published Date: 8 June 2026
Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis
Akbari AM, Bourbour S, Seyedmehdi MS, Shiari S, Rustamzadeh A, Seif F, Farivar S
Biologics: Targets and Therapy 2026, 20:603545
Published Date: 29 May 2026
MicroRNA-661 Suppresses Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells and Endothelial Cells by Targeting CCND2
Jiang L, Yang A, Liu J, Zhou J
Biologics: Targets and Therapy 2026, 20:592879
Published Date: 28 May 2026
Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review
Deng S, Jiang Y, Li W, Shu Z, Chen T, Liang J, Zhang X
Biologics: Targets and Therapy 2026, 20:592069
Published Date: 22 May 2026
Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report
Ma D, Li Z
Biologics: Targets and Therapy 2026, 20:595201
Published Date: 20 May 2026
Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience
Triana P, Marín E, Mendieta C, Fernández L, Rodriguez-Laguna L, Lopez-Gutierrez JC
Biologics: Targets and Therapy 2026, 20:606831
Published Date: 19 May 2026
Optimization of Recombinant Human Interferon-Gamma Expression and Purification in E. coli, and Developing an Immunization Protocol for the Production of Optimal Humoral Response
Uwituze V, Mugasa CM, Namayanja M, Nalumenya DP, Ndayisenga J, Ssekatawa K, Kato CD
Biologics: Targets and Therapy 2026, 20:584180
Published Date: 16 April 2026
Enhancement of Gastric Mucosal Defense by Phytomedicine in the Context of H. pylori–Associated Ulcer Disease
Paulraj RS, Perumal P, Ramachandran A, Sathiyaseelan A
Biologics: Targets and Therapy 2026, 20:597797
Published Date: 14 April 2026
Rheumatoid Factor Beyond Rheumatoid Arthritis: A Potential Marker of Cardiometabolic and Hepatic Risk
Egba SI, Orhonigbe IO, Achi NK, Ikechukwu GC, Chukwu CN, Omeoga CH
Biologics: Targets and Therapy 2026, 20:603345
Published Date: 13 April 2026
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review
Elimam N, Albarari SS, Shaalan Y, Elsheikh SM, Alzamari AA, Elmekkawi N, Mogahed R, Alghuweiri RH
Biologics: Targets and Therapy 2026, 20:593367
Published Date: 31 March 2026
Anifrolumab in Refractory Oral Manifestations in Systemic Lupus Erythematosus: A Case Report and Literature Review
Garmish O, Smiyan S, Komorovsky R, Bilozetskyi I
Biologics: Targets and Therapy 2026, 20:588071
Published Date: 16 March 2026
Late-Onset Ocular Myasthenia Gravis–Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report
Qaqish A, Al Anber A, Abdelhafez G
Biologics: Targets and Therapy 2026, 20:579731
Published Date: 4 March 2026
First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison
Zhu Y, Qi X, Ni S, Qiu W, Chen M
Biologics: Targets and Therapy 2026, 20:602654
Published Date: 28 February 2026
Network Pharmacology-Based Exploration: Non-Targeted Metabolites of Lactobacillus-Fermented Chaenomeles speciosa (Sweet) Nakai, Smilax glabra Roxb. and Pueraria montana var. Lobata in Uric Acid Metabolism Intervention
Tan W, Li Z
Biologics: Targets and Therapy 2026, 20:578004
Published Date: 24 February 2026
Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development
Ranbhor R, Kulkarni P
Biologics: Targets and Therapy 2026, 20:581013
Published Date: 10 February 2026
Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab
Otake H, Matsumoto S, Mashima H
Biologics: Targets and Therapy 2026, 20:561965
Published Date: 20 January 2026
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
Piron B, Moreau P, Touzeau C
Biologics: Targets and Therapy 2026, 20:539066
Published Date: 13 January 2026
Research on the Role of Autophagy in Vascular Endothelial Cells in the Healing of Chronic Refractory Wounds
Riling L, Kunyue F, Liyan G, Yaya W, Baoling N, Jiehui L
Biologics: Targets and Therapy 2026, 20:573844
Published Date: 13 January 2026
Mesenchymal Stem Cell Therapy in Osteoarthritis and Rheumatoid Arthritis: A Systematic Review of Exosomal microRNAs
Hejazian SS, Hejazian SM, Mostafavi Montazeri SS, Abediazar S, Zununi Vahed S, Barzegari A
Biologics: Targets and Therapy 2025, 19:747-785
Published Date: 30 December 2025
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing [Corrigendum]
Asmamaw M, Zawdie B
Biologics: Targets and Therapy 2025, 19:745-746
Published Date: 27 December 2025
Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study
Pápista M, Resál T, Bacsur P, Kata D, Farkas B, Bálint A, Fábián A, Bor R, Ivány E, Szepes Z, Farkas K, Juhász Z, Buzás N, Molnár T
Biologics: Targets and Therapy 2025, 19:731-743
Published Date: 18 December 2025
LncRNA GAS5 Modulates the Progression of Glioma Through Repressing miR-135b-5p and Upregulating APC [Corrigendum]
Zhang J, You Q, Wang Y, Ji J
Biologics: Targets and Therapy 2025, 19:729-730
Published Date: 10 December 2025
Switch from Intravenous to Subcutaneous Formulation of Tocilizumab in Rheumatoid Arthritis: Retrospective Cohort Analysis and Systematic Literature Review
Galoppini G, Garaffoni C, Lotesoriere A, Nogarin F, Bortoluzzi A, Govoni M, Silvagni E
Biologics: Targets and Therapy 2025, 19:713-727
Published Date: 4 December 2025
Tumor-to-Tumor Metastasis: Breast Cancer Metastasizing to EGFR Exon 19-Mutated Lung Adenocarcinoma with Long-Term Disease-Free Survival
Zhang Y, Hao Y, Yang H, Meng X, Yang S, Wang J, Xie J, Lu P, Ji Y
Biologics: Targets and Therapy 2025, 19:707-712
Published Date: 19 November 2025
In Silico Screening of Streptomyces sp. Metabolites Targeting P. falciparum DHODH and DPCK for Antimalarial Discovery
Hamami SMA, Riswana FR, Fitri LE, Widodo N, Zakaria MNZ, Aththar AF, Khairi ER, Abdullah A, Prasetya DY, Fai M
Biologics: Targets and Therapy 2025, 19:681-705
Published Date: 15 November 2025
Beyond Monotherapy: Exploring the Efficacy and Safety of Dual Biologic Strategies in Rheumatic Diseases
Hassan F, Jeries H, Daood R, Naffaa ME
Biologics: Targets and Therapy 2025, 19:665-680
Published Date: 8 November 2025
Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0)
Bracalenti M, Zen M, Bianchi B, Bortoluzzi A, Brussino L, Castrignanò P, Cauli A, Cavagna L, Chessa E, Chiara E, De Angelis R, De Marchi G, Di Carlo M, Emmi G, Galvagni I, Gasparotto M, Gatto M, Gerli R, Govoni M, Lo Gullo A, Nano A, Negrini S, Noviello S, Orsolini G, Pazzola G, Piga M, Quartuccio L, Rossini M, Salvarani C, Silvagni E, Silvestri E, Tamussin M, Tizian M, Tomietto P, Urban ML, Vacca A, Doria A, Iaccarino L
Biologics: Targets and Therapy 2025, 19:651-663
Published Date: 30 October 2025
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson B, Chan P
Biologics: Targets and Therapy 2025, 19:631-649
Published Date: 27 October 2025
The Dual Role of the TRAIL-DR5 Signaling Axis in Cardiovascular Disease: From Molecular Mechanisms to Targeted Therapies
Cao R, Qi W, Huang X, Zheng Y, Zheng R, Ma Y, Zhang H
Biologics: Targets and Therapy 2025, 19:613-629
Published Date: 25 October 2025
Irisin Research Landscape (2012–2024): A Bibliometric and Visual Analysis of Evolving Hotspots and Future Trends
Gao L, Sun W, Shi H, Zhu W, Wang H, Wang J
Biologics: Targets and Therapy 2025, 19:595-611
Published Date: 22 October 2025
The Potential of Telitacicept in Treating Lupus erythematosus panniculitis: A Case Report
Xie X, Tang S, Huang M
Biologics: Targets and Therapy 2025, 19:585-593
Published Date: 7 October 2025
Dual Blocking of IL17A and IL36R for the Treatment of Refractory Hidradenitis Suppurativa: A Case Report
Yu Y, Li J, Liu H, Sun Y, Zhang F
Biologics: Targets and Therapy 2025, 19:581-584
Published Date: 3 October 2025
Migrasomes: A New Role in Disease Diagnosis and Treatment
Zhang X, Wang S, Jiang Y, Zhu W, Yang Y, Huo L, Zhang Y, Zhou Y, Yang Z, Wang X
Biologics: Targets and Therapy 2025, 19:561-579
Published Date: 2 October 2025
siRNAs, tRNAs, and rRNAs in Osteoarthritis: Biological Functions and Therapeutic Opportunities
Wang M, Dai Y, Ge X, Zheng L, Zhai M, Li W, Liu G, Cheng X, Wei J, Yang X, Liu L, Liu H, Sun J, Li B, Yuan F
Biologics: Targets and Therapy 2025, 19:539-560
Published Date: 3 September 2025
Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis
Xu C, Wang SI, Leung YY, Wei JCC
Biologics: Targets and Therapy 2025, 19:525-538
Published Date: 30 August 2025
Enhancing Early Detection of Pancreatic Cancer in Genetically Predisposed Individuals: Integrating Advanced Imaging Modalities with Emerging Biomarkers and Liquid Biopsy
Abdel-Razeq R, Mansour A, Barbar M, Abu Shanap M, Sharaf B, Tamimi F, Mansour R, Muhanna A, Al-Othman Y, Hammad H, Shakhatreh M, Mahafdah S, Bani Hani H, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:511-523
Published Date: 30 August 2025
Therapeutic Potential of Compounds with High Affinity to BAG2 in Inhibiting Keloid Disease
Wang Y, Yuan Z, Zhou R, Lu L, Wang X, Yang J
Biologics: Targets and Therapy 2025, 19:497-510
Published Date: 24 August 2025
What’s New and What’s Next in Fecal Microbiota Transplantation?
Baydoun H, Hussain N, Wu KO, Kelly CR, Fischer M
Biologics: Targets and Therapy 2025, 19:481-496
Published Date: 21 August 2025
Activated Growth Factor (AGF) as a Superior Biological Therapy for Osteoarthritis: Comparative Efficacy in Modulating Cartilage Degeneration and Inflammation in vivo
Hidayat R, Harun Z
Biologics: Targets and Therapy 2025, 19:463-479
Published Date: 21 August 2025
Investigating the Oncogenic and Immunological Implications of YTHDF1 in Ovarian Cancer
Yin B, Zhou H
Biologics: Targets and Therapy 2025, 19:443-462
Published Date: 12 August 2025
Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review
Civino A, Diomeda F, Burrone M, Natoli V, Ravelli A
Biologics: Targets and Therapy 2025, 19:425-441
Published Date: 23 July 2025
Regarding “Effectiveness and Persistence of Anti-TNFα Treatment in Patients with Rheumatoid Arthritis – A 7 Years Real-World Cohort Study” [Response to Letter]
Santos-Moreno P
Biologics: Targets and Therapy 2025, 19:423-424
Published Date: 17 July 2025
Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning
Babaei N, Gill M, Cervantes M, Kim D, Yang S, Wu JJ
Biologics: Targets and Therapy 2025, 19:415-422
Published Date: 15 July 2025
Regarding “Effectiveness and Persistence of Anti-TNFα Treatment in Patients with Rheumatoid Arthritis - A 7 Years Real-World Cohort Study” [Letter]
Borrás-Blasco J, Valcuende-Rosique A, Cornejo-Uixeda S
Biologics: Targets and Therapy 2025, 19:413-414
Published Date: 7 July 2025
Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats
Hama Said HJ, Ahmed ZA
Biologics: Targets and Therapy 2025, 19:399-412
Published Date: 3 July 2025
IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa
Zhang H, Liu Z, Qin B, Cheng D, Chen P, Bi X
Biologics: Targets and Therapy 2025, 19:387-397
Published Date: 30 June 2025
Marstacimab for the Treatment of Hemophilia A or B
Mahlangu J
Biologics: Targets and Therapy 2025, 19:379-386
Published Date: 24 June 2025
Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge
Yang H, Yang L, Liu Y, Wang L
Biologics: Targets and Therapy 2025, 19:365-377
Published Date: 31 May 2025
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s Disease
D’Amico F, Bencardino S, Magro F, Dignass A, Gutiérrez Casbas A, Verstockt B, Hart A, Armuzzi A, Peyrin-Biroulet L, Danese S
Biologics: Targets and Therapy 2025, 19:351-363
Published Date: 31 May 2025
Targeting CREBRF in Cancer: Mechanistic Insights and Future Directions
Lv B, Zhang D
Biologics: Targets and Therapy 2025, 19:341-350
Published Date: 30 May 2025